Lynparza improved the time women lived without disease progression
30 September 2019 07:00 BST Lynparza improved the time women lived without disease progression to 22 months in the broad population and to 37 months in HRD-positive patients as 1st-line maintenance treatment with bevacizumab for newly-diagnosed advanced ovarian cancer AstraZeneca and MSD's Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced detailed positive results from the Phase III PAOLA-1